Drugs / SGN-30
Trials 7
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-12-05 | Pfizer | Results Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS pfizer.com ↗
Data from more than 75 company-sponsored, investigator-sponsored, and collaborative research abstracts will be presented at ASH, including updated analyses from the pivotal ECHELON-3 trial supporting the clinical benefit of ADCETRIS ® (brentuximab vedotin) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). |
| 2024-06-01 | Pfizer | Results Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma pfizer.com ↗
The four-year analysis presented by the GHSG showed superior progression-free survival (PFS) and improved tolerability for patients compared to a current standard of care regimen used in Europe in this setting. |
| 2024-06-01 | Pfizer | Results Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) pfizer.com ↗
The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0.0085). |
| 2024-04-29 | Pfizer | Results Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting pfizer.com ↗
Results from ECHELON-3, third Phase 3 study to demonstrate overall survival benefit for ADCETRIS ® (brentuximab vedotin) in a type of lymphoma |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354107 ↗ |
| Known as | Brentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02623920 ↗ |
| Action | Inhibit | “Monoclonal antibodies, such as SGN-30, may interfere with the ability of cancer cells to grow and spread.” NCT00337194 ↗ |
| Modality | Monoclonal antibody | “Phase 1 testing of SGN-30, a chimeric monoclonal antibody for the treatment of CD30(+) malignancies, was conducted in a multicenter study.” PMID 18079362 ↗ Dec 2007 |
| Route | Intravenous | “received 6 weekly doses of intravenous SGN-30 at 4 dose levels (2, 4, 8, or 12 mg/kg).” PMID 18079362 ↗ Dec 2007 |